ARZ-003

**ARZ-003** is an investigational Artizan Biosciences therapeutic candidate emerging from the company's microbiome-informed discovery platform for inflammatory and digestive diseases. Publicly available information is very limited, but ARZ-003 has been described as one of Artizan's pipeline assets expected to follow ARZC-001 into the clinic, and third-party pipeline sources have associated it with digestive system disorders and irritable bowel syndrome. Its precise molecular identity, target, modality-specific mechanism, formulation, and route of administration have not been clearly disclosed in accessible primary public sources, so it is best characterized as a preclinical or discovery-stage proprietary drug candidate for gastrointestinal disease rather than a clinically validated, mechanistically defined medicine.